"Don’t delay your care: you can schedule in-office appointments or video visits with NYU Langone doctors online. Every precaution is in place to ensure our facilities are safe so you can get the care you need. Visit our website for more details."

During the past decade, NYU Comprehensive Epilepsy Center conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 7 clinical trials were completed, i.e. on average, 43.8% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 6 clinical trials were completed. i.e. 60% of trials that started reached the finish line.

Out of the total clinical trials conducted in "NYU Comprehensive Epilepsy Center" #1 sponsor was "Eisai Inc." with 4 trials, followed by "Marinus Pharmaceuticals" with 3 trials sponsored, "Takeda" with 3 trials sponsored, "Jazz Pharmaceuticals" with 2 trials sponsored and "Stoke Therapeutics, Inc" with 2 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "NYU Comprehensive Epilepsy Center" #1 collaborator was "GlaxoSmithKline" with 2 trials as a collaborator, "California Institute for Regenerative Medicine (CIRM)" with 1 trials as a collaborator, "Eisai Inc." with 1 trials as a collaborator, "H. Lundbeck A/S" with 1 trials as a collaborator and "Johnson & Johnson Pharmaceutical Research & Development, L.L.C." with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "NYU Comprehensive Epilepsy Center" are "Epilepsy" (4 trials), "Dravet Syndrome" (3 trials), "Tuberous Sclerosis Complex" (3 trials), "Dravet Syndrome (DS)" (2 trials) and "Lennox Gastaut Syndrome" (2 trials). Many other conditions were trialed in "NYU Comprehensive Epilepsy Center" in a lesser frequency.

Most popular intervention types in "NYU Comprehensive Epilepsy Center" are "Drug" (22 trials), "Biological" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "Soticlestat" (3 trials), "Rufinamide" (2 trials), "CX-8998" (1 trials) and "E2007 (perampanel)" (1 trials). Other intervention names were less common.

The vast majority of trials in "NYU Comprehensive Epilepsy Center" are 25 trials for "All" genders.

Currently, there are NaN active trials in "NYU Comprehensive Epilepsy Center". undefined are not yet recruiting, 8 are recruiting, 2 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 12 completed trials in NYU Comprehensive Epilepsy Center, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in NYU Comprehensive Epilepsy Center, 2 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".